FDA considers new efficacy endpoint for diabetes drugs

Regulatory News

Regulatory NewsJoanne S. Eglovitch

Biologics/ biosimilars/ vaccinesClinical TrialsNorth AmericaPharmaceuticalsRegulatory Intelligence/Policy